Rocbrutinib plus R-CHOP for newly diagnosed B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new targeted drug called rocbrutinib combined with the standard chemo-immunotherapy R-CHOP for people newly diagnosed with certain types of B-cell non-Hodgkin lymphoma. The goal is to see if adding rocbrutinib helps the standard treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of one of the following: diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).
- You cannot have had any prior cancer treatment (such as chemotherapy or radiation) for this lymphoma.
- You must have at least one tumor that can be measured on a scan.
- You should be in fairly good health (ECOG score 0–2, meaning you can do daily activities with little or no help).
- Your liver, kidneys, and blood levels must be within certain limits (your doctor will check this).
- If you have DLBCL, you may need an IPI score of 2 or higher (a measure of risk).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining a new drug called rocbrutinib with standard chemotherapy (R-GemOx) works better for patients whose diffuse large B-cell lymphoma (a type of blood cancer) has stopped responding to previous treatments. Researchers hope this combination may help patients who have limited options.
This study tests a new combination of targeted drugs (zanubrutinib, chidamide, and rituximab) with or without standard chemotherapy (CHOP) versus the usual R-CHOP regimen for people with a specific type of aggressive DLBCL (double-expressor). The goal is to see if the new approach works better.
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.